Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Semaglutid til forebyggelse af diabetes efter transplantation mellitus (SPOT-DM)

4. november 2026 opdateret af: Sunita Singh, MD, MSc, FRCPC, University Health Network, Toronto

The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of semaglutide therapy in 37 KTR at risk of post-transplant diabetes mellitus (PTDM).

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

A kidney transplant is the best treatment for people living with kidney failure as it allows people to live longer with a better quality of life. However, one in four kidney transplant recipients will develop diabetes after transplant. This is largely due to the medications that must be used to prevent rejection of the transplant. Kidney transplant recipients who get diabetes after transplant are up to three times more likely to have heart disease and die prematurely. To date, there are no treatments to prevent the development of diabetes after kidney transplant. Semaglutide is a drug that is commonly used to treat diabetes and obesity. The investigators believe that semaglutide is a safe and effective drug which can prevent the development of diabetes in kidney transplant recipients. Therefore, the investigators are conducting a study where kidney transplant recipients who are at increased risk of developing diabetes after transplant will receive semaglutide for 24 weeks after their transplant. The study will determine whether semaglutide is effective in decreasing blood sugar levels and the rate of diabetes. The investigators will also study other important markers of health including body weight and cholesterol levels as well as liver, kidney and heart function. Diabetes after transplant is a common problem, and preventing it is extremely important to allowing kidney transplant recipients to live longer and better lives. The results of this study will allow the investigators to determine if semaglutide is a safe and effective option for the prevention of diabetes in kidney transplant recipients.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

37

Fase

  • Fase 2
  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • British Columbia
      • Vancouver, British Columbia, Canada, V6Z 1Y6
        • St. Paul's Hospital
        • Kontakt:
    • Ontario
      • Toronto, Ontario, Canada, M5G 2N2
        • Toronto General Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Sunita Singh, MD MSc FRCPC

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Signed and dated written informed consent.

  2. Adult (≥18 years) recipients of a living or deceased donor kidney transplant

  3. Between 4- and 12-weeks post kidney transplant

  4. Stable kidney function defined as an eGFR > 30 ml/min/1.73m2 (CKD-EPI)

  5. At risk for PTDM at the time of transplant based on the following criteria:

    1. BMI ≥ 25 kg/m2, or
    2. Fasting plasma glucose 6.1-6.9 mmol/L (impaired fasting glucose), or
    3. 2hr OGTT plasma glucose 7.8-11.0 (impaired glucose tolerance), or
    4. HbA1C 5.5-6.4% (at risk for DM or prediabetes).

Exclusion Criteria:

  1. Established diagnosis of type 1 or type 2 DM as per Diabetes Canada (including the need for glucose-lowering therapy for hyperglycemia at the time of screening)
  2. Kidney-Pancreas transplant recipient
  3. Acute coronary syndrome, transient ischemic attack or stroke within 30 days prior to screening
  4. History of pancreatitis
  5. Personal or family history of medullary thyroid cancer or MEN2B
  6. Women who are pregnant, nursing or plan on becoming pregnant whilst in the trial
  7. Use of GLP1RA in the 30 days prior to screening
  8. Contraindication to MRI (applicable only to those undergoing the optional MRI assessments)
  9. With known or suspected hypersensitivity to semaglutide or related products
  10. Patient not able to understand and comply with study requirements, based on Investigator's judgment.
  11. Any other clinical condition that, based on Investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcom
  12. History of glucose-galactose malabsorption syndrome

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Semaglutide

Patients will be up-titrated as tolerated starting at 0.25 mg subcutaneous semaglutide once weekly for 4 weeks, followed by 0.5 mg, 1.0 mg, and 1.7 mg semaglutide for 4 weeks each, and then 2.4 mg subcutaneous semaglutide once weekly for 8 weeks. Semaglutide can be down-titrated by the investigator to lower doses or up-titrated at slower rates if not tolerated by the participant.

Subcutaneous semaglutide 0.25mg for 4 weeks.

Subcutaneous semaglutide 0.5mg for 4 weeks.

Subcutaneous semaglutide 1.0 mg for 4 weeks.

Subcutaneous semaglutide 1.7 mg for 4 weeks

Subcutaneous semaglutide 2.4 mg for 8 weeks

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
2-hour OGTT
Tidsramme: 24 weeks

The primary outcome of this study is the change in plasma glucose at 120 minutes following a 75g oral glucose challenge (2-hour OGTT) at 24 weeks. The 2-hour OGTT was selected as the primarily outcome in this study for the following reasons: 1) In selecting a surrogate outcome for PTDM in KTR, there are limitations to HbA1c and fasting glucose in this population; 2) The 2-hour OGTT is the recommended test for the diagnosis of PTDM in KTR and 3) The use of OGTT has been used in other PTDM prevention studies.

24 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Systolisk blodtryk
Tidsramme: 24 uger
24 uger
Ændring i kropsvægt
Tidsramme: 24 uger
24 uger
Ændring i taljeomkreds
Tidsramme: 24 uger
24 uger
Ændring i HbA1c
Tidsramme: 24 uger
24 uger
Ændring i fastende blodsukker
Tidsramme: 24 uger
24 uger
Ændring i seruminsulin
Tidsramme: 24 uger
24 uger
Ændring i fastende lipidprofil
Tidsramme: 24 uger
24 uger
Diastolisk blodtryk
Tidsramme: 24 uger
24 uger
Gennemsnitligt arterielt tryk
Tidsramme: 24 uger
24 uger
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Tidsramme: 24 weeks

: The side effects of GLP-1RA have been well described and will be assessed at each study visit. Adverse events include AKI, hypoglycemia, volume depletion, GI intolerance, amputations, pancreatitis, hepatobiliary complications and injection site or allergic reactions, infectious complications (any source), and malignancy. Episodes of biopsy-proven acute rejection (as defined by the Banff criteria), death-censored graft failure (defined as the need for initiation of chronic dialysis or re-transplantation) or death with graft function (defined as death with a functioning allograft) will also be collected. Kidney transplantation assures complete denervation of the transplanted kidney and the renal vasoconstrictive response in the setting of intravascular volume depletion is diminished in KTR. Therefore, frequent monitoring for adverse events has been integrated in our study design, occurring on 10 separate occasions, to capture these adverse events should they occur.

24 weeks
Estimated GFR
Tidsramme: 24 weeks

Calculated by CKD-EPI 2021 equation

24 weeks
GFR
Tidsramme: 24 weeks

Measured using 24-urine collection for creatinine, standardized per 1.73m2 body surface area. And estimated using CKD-EPI 2021 equation.

24 weeks
Albuminuria
Tidsramme: 24 weeks

measuring urine albumin excretion from a 24-hour urine collection

24 weeks
Natriuresis
Tidsramme: 24 weeks

Assessed with a 24-hour urine collection for sodium excretion

24 weeks
Percentage of body fat
Tidsramme: 24 weeks

Bioimpedance analysis

24 weeks
Change in liver enzymes
Tidsramme: 24 weeks

ALT and AST

24 weeks
Change in fibrosis level
Tidsramme: 24 weeks

Transient elastography

24 weeks
Change in steatosis level
Tidsramme: 24 weeks

Transient elastography

24 weeks
Percentage of extracellular fluid
Tidsramme: 24 weeks

Bioimpedance analysis

24 weeks

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in kidney oxygenation (R2*)
Tidsramme: 24 weeks

Assessed via multiparametric kidney MRI in an optional cohort.

24 weeks
Change in kidney fibrosis (ADC)
Tidsramme: 24 weeks

Assessed via multiparametric kidney MRI in an optional cohort.

24 weeks
Change in kidney perfusion
Tidsramme: 24 weeks

Assessed via multiparametric kidney MRI in an optional cohort.

24 weeks
Change in kidney volume
Tidsramme: 24 weeks

Assessed via multiparametric kidney MRI in an optional cohort.

24 weeks
Change in kidney inflammation (T1)
Tidsramme: 24 weeks

Assessed via multiparametric kidney MRI in an optional cohort.

24 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Sunita Singh, MD MSc FRCPC, University Health Network, Toronto General Hospital

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

5. december 2026

Primær færdiggørelse (Anslået)

30. juni 2029

Studieafslutning (Anslået)

30. december 2029

Datoer for studieregistrering

Først indsendt

17. marts 2025

Først indsendt, der opfyldte QC-kriterier

2. april 2025

Først opslået (Faktiske)

6. april 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

4. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 25-5093

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .